Search Results for "Drug Interactions"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug Interactions. Results 701 to 710 of 1090 total matches.
Ferric Citrate (Auryxia) for Hyperphosphatemia
The Medical Letter on Drugs and Therapeutics • Dec 07, 2015 (Issue 1483)
abortion, gestational diabetes, and
fetal malformations.
DRUG INTERACTIONS — Iron-containing products ...
The FDA has approved ferric citrate (Auryxia –
Keryx), an oral phosphate binder, for treatment of
hyperphosphatemia in patients with chronic kidney
disease (CKD) on dialysis. It is the second iron-based
phosphate binder to be approved in the US, and the
first that causes significant systemic absorption of
iron. Auryxia is not FDA-approved for treatment of
iron deficiency anemia.
Mobocertinib (Exkivity) for Non-Small Cell Lung Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Nov 28, 2022 (Issue 1664)
be monitored before starting mobocertinib and
periodically during treatment.
DRUG INTERACTIONS — Concurrent ...
Mobocertinib (Exkivity – Takeda), an oral kinase
inhibitor, has received accelerated approval from the
FDA for treatment of locally advanced or metastatic
non-small cell lung cancer (NSCLC) with epidermal
growth factor receptor (EGFR) exon 20 insertion
mutations in adults whose disease has progressed on
or after platinum-based chemotherapy. Accelerated
approval was based on the overall response rate and
duration of response. Mobocertinib is the second
drug to become available in the US for this indication;
the IV EGFR-MET bispecific antibody amivantamab
(Rybrevant) was approved...
Cilostazol for Intermittent Claudication
The Medical Letter on Drugs and Therapeutics • May 07, 1999 (Issue 1052)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
Cilostazol, a phosphodiesterase III inhibitor that has been used in Japan since 1988, has been approved by the FDA for treatment on intermittent claudication due to occlusive peripheral arterial disease.
Dabrafenib (Tafinlar) and Trametinib (Mekinist) for Metastatic Melanoma
The Medical Letter on Drugs and Therapeutics • Aug 05, 2013 (Issue 1422)
as category
D (positive evidence of risk) for use during pregnancy.
DRUG INTERACTIONS — Dabrafenib ...
The FDA has approved two new oral kinase inhibitors for
treatment of unresectable or metastatic melanoma:
dabrafenib (Tafinlar – GSK) for melanomas with BRAF
V600E mutations and trametinib (Mekinist – GSK) for
melanomas with either BRAF V600E or V600K mutations.
Dabrafenib is not recommended for patients with
wild-type BRAF (BRAF-negative) melanoma, and trametinib
is not recommended for patients who have
received prior BRAF-inhibitor therapy.
Deflazacort (Emflaza) for Duchenne Muscular Dystrophy
The Medical Letter on Drugs and Therapeutics • Sep 11, 2017 (Issue 1529)
drug to be approved for treatment of DMD; eteplirsen
(Exondys 51), an antisense oligonucleotide ...
Deflazacort (Emflaza – PTC Therapeutics), an oral
corticosteroid, has been approved by the FDA for
treatment of Duchenne muscular dystrophy (DMD) in
patients ≥5 years old. It has been available outside
the US for many years. Deflazacort is the second
drug to be approved for treatment of DMD; eteplirsen
(Exondys 51), an antisense oligonucleotide approved
for IV administration in patients with mutations of
the dystrophin gene amenable to exon 51 skipping
(about 13% of DMD cases), was the first.
Enfuvirtide (Fuzeon) for HIV infection
The Medical Letter on Drugs and Therapeutics • Jun 23, 2003 (Issue 1159)
CYP450 enzymes; drug interactions have not been reported. It is not fetotoxic in animals.
DOSAGE ...
Enfuvirtide (T-20; Fuzeon Trimeris/Roche), the first in a new class of HIV drugs known as fusion inhibitors, has received accelerated approval from the FDA for use with other antiretrovirals in adults and children with viral replication despite ongoing antiretroviral therapy. This review describes the mechanism of action and pharmacokinetics of the new drug, and outlines the results of the 2 clinical studies that led to its approval. Sections on adverse effects, development of resistance, and dosage and cost are also included. The review concludes with an overall assessment of the...
Perampanel (Fycompa) for Epilepsy
The Medical Letter on Drugs and Therapeutics • Feb 03, 2014 (Issue 1435)
pregnancy.
10 The Medical Letter • Volume 56 • Issue 1435 • February 3, 2014
DRUG INTERACTIONS ...
Perampanel (per am’ pa nel; Fycompa – Eisai), a first-in-class noncompetitive AMPA receptor antagonist, has
been approved by the FDA for adjunctive treatment of
partial-onset seizures in patients ≥12 years old. New
drugs for epilepsy are often initially approved by the
FDA as adjunctive treatment for partial seizures.
InstaRead Lithium System
The Medical Letter on Drugs and Therapeutics • Oct 10, 2005 (Issue 1219)
. The Medical Letter Adverse Drug Interactions Program available at www.medicalletter.org/html/software_desc2 ...
The InstaRead Lithium System (ReliaLAB), an office test that only requires a finger stick to measure lithium serum concentrations, has been cleared by the FDA and is now available. Standard methods for measuring lithium serum concentrations require venipuncture and transport of the specimen to commercial laboratories.
Ribociclib (Kisqali) for Advanced or Metastatic Breast Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Oct 23, 2017 (Issue 1532)
.
DRUG INTERACTIONS — Ribociclib is a substrate
of CYP3A4; concurrent administration of strong
CYP3A ...
The oral cyclin-dependent kinase (CDK) 4/6 inhibitor
ribociclib (Kisqali – Novartis) has been approved by
the FDA for use in combination with an aromatase
inhibitor for first-line endocrine-based therapy in
postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor
2 (HER2)-negative advanced or metastatic breast
cancer. Ribociclib is also available copackaged
with the aromatase inhibitor letrozole (Femara, and
generics) as Kisqali Femara Co-Pack. Ribociclib is
the second CDK 4/6 inhibitor to be approved in the US
for this indication;...
Drospirenone (Slynd) - A New Progestin-Only Oral Contraceptive
The Medical Letter on Drugs and Therapeutics • Feb 10, 2020 (Issue 1591)
uterine bleeding.
DRUG INTERACTIONS — Drospirenone is partly
metabolized by CYP3A4. Drugs that induce ...
The FDA has approved a progestin-only oral
contraceptive ("minipill") containing drospirenone
(Slynd – Exeltis). All other progestin-only oral
contraceptives available in the US contain
norethindrone (Camila, and others). Progestin-only oral
contraceptives are similar in efficacy to combination
oral contraceptives. They are used predominantly by
breastfeeding women and by those in whom estrogen
is poorly tolerated or contraindicated. Combination
oral contraceptives containing drospirenone and
ethinyl estradiol have been available for years.